All Stories

  1. Owner-reported experiences are similar for dogs experiencing euthanasia or unassisted death: evaluation of the Dog Aging Project’s End of Life Survey free-text responses
  2. Gastric dilatation-volvulus is associated with Poodle breeds, increased body size, and male sex, but not primary diet type or anxiety in the Dog Aging Project cohort
  3. Supplement use is common in Dog Aging Project participants, especially among dogs with orthopedic conditions, and varies by life stage
  4. Findings from the Dog Aging Project: home-prepared diets for companion dogs feature diverse ingredients, and few are nutritionally complete
  5. An analysis of behavioral characteristics and enrollment year variability in 47,444 dogs entering the Dog Aging Project from 2020 to 2023
  6. Environmental exposures and health outcomes in dogs differ according to geographic region in the United States among Dog Aging Project participants
  7. Self-reported dog vaccination practices in pet owners enrolled in the Dog Aging Project in the United States found most dogs were vaccinated according to veterinarians’ recommendations
  8. Voided urine collection for urine culture in female dogs with lower urinary tract signs is not a substitute for cystocentesis
  9. Comparing owner reported and genetic breed identification reveals high concordance in a large cohort from the Dog Aging Project
  10. Testing for heavy metals in drinking water collected from Dog Aging Project participants
  11. Gonadectomy status and age are associated with variable risk of overweight or obese outcomes in 15 dog breeds: a retrospective cohort study using data from primary care veterinary clinics
  12. Development and validation of a chronic diagnosis inventory that enables reliable documentation of canine multimorbidity in the Dog Aging Project
  13. WITHDRAWN: Self-reported dog vaccination practices in pet owners enrolled in the Dog Aging Project in the United States found most dogs were vaccinated according to veterinarians’ recommendations
  14. Food motivation and owner feeding management practices are associated with overweight among Dog Aging Project participants
  15. Using pet insurance claims to predict occurrence of vector-borne and zoonotic disease in humans in the United States
  16. Association Between Diet Type and Owner‐Reported Health Conditions in Dogs in the Dog Aging Project
  17. Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2
  18. Rationale and design of the Dog Aging Project precision cohort: a multi-omic resource for longitudinal research in geroscience
  19. Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project
  20. The effects of resting time, centrifugation time, and technician training on plasma sample quantity and quality: Implications for the Dog Aging Project
  21. Genetic, epigenetic, and environmental factors influencing dog lifespan
  22. Dog and owner demographics impact dietary choices in Dog Aging Project cohort
  23. Cross-sectional survey of 43,517 dogs in the Dog Aging Project identifies owner-reported lifetime prevalence and characteristics of gastrointestinal disease
  24. Aging at scale: Younger dogs and larger breeds from the Dog Aging Project show accelerated epigenetic aging
  25. Testing for heavy metals in drinking water collected from Dog Aging Project participants
  26. Aligning valid research outcomes with stakeholder values—what do they need for decision-making?
  27. How can we achieve more accurate reporting of average dog lifespan?
  28. Silicone tags as an effective method of monitoring environmental contaminant exposures in a geographically diverse sample of dogs from the Dog Aging Project
  29. Using pet insurance claims to predict occurrence of vector-borne and zoonotic disease in humans
  30. Characterizing dog cognitive aging using spontaneous problem-solving measures: development of a battery of tests from the Dog Aging Project
  31. Exposure variables in veterinary epidemiology: are they telling us what we think they are?
  32. Canine sentinels and our shared exposome
  33. The companion dog as a model for inflammaging: a cross-sectional pilot study
  34. What question are we trying to answer? Embracing causal inference
  35. Factors associated with behavioral euthanasia in pet dogs
  36. Validation of the shortened version of the Canine Behavioral Assessment and Research Questionnaire (C-BARQ) using participants from the Dog Aging Project
  37. Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study
  38. Analysis of 2,570 responses to Dog Aging Project End of Life Survey demonstrates that euthanasia is associated with cause of death but not age
  39. Dog size and patterns of disease history across the canine age spectrum: Results from the Dog Aging Project
  40. “I Like to Know When My Period’s Coming”: How Menstruators Use Technology to Track, Monitor, and Manage Their Menses
  41. Lifetime prevalence of owner-reported medical conditions in the 25 most common dog breeds in the Dog Aging Project pack
  42. Age at gonadectomy, sex, and breed size affect risk of canine overweight and obese outcomes: a retrospective cohort study using data from United States primary care veterinary clinics
  43. Development and validation of a novel instrument to capture companion dog mortality data: the Dog Aging Project End of Life Survey
  44. “Sometimes I just forget them”: capturing experiences of women about free menstrual products in a U.S. based public university campus
  45. A review of frailty instruments in human medicine and proposal of a frailty instrument for dogs
  46. Approaches Used to Construct Antibiograms for Dogs in a Veterinary Teaching Hospital in the United States
  47. Predicting health outcomes in dogs using insurance claims data
  48. Author Correction: Evaluation of cognitive function in the Dog Aging Project: associations with baseline canine characteristics
  49. Approaches Used To Construct Antibiograms for Dogs in a Veter-Inary Teaching Hospital in the United States
  50. Antimicrobial Susceptibility of Bacteria Isolated from Freshwater Mussels in the Wildcat Creek Watershed, Indiana, United States
  51. Data from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  52. Data from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  53. Figure S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  54. Figure S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  55. Figure S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  56. Figure S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  57. Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  58. Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  59. Figure S4 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  60. Figure S4 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  61. Figure S5 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  62. Figure S5 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  63. Figure S6 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  64. Figure S6 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  65. Supplementary Table S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  66. Supplementary Table S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  67. Supplementary Table S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  68. Supplementary Table S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  69. Supplementary Table S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  70. Supplementary Table S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
  71. Development and Validation of a Novel Instrument to Capture Companion Dog Mortality Data: The Dog Aging Project End of Life Survey
  72. The standards of reporting randomized trials in pets (PetSORT): Methods and development processes
  73. The standards of reporting trials in pets (PetSORT): Explanation and elaboration
  74. Banking on a new understanding: translational opportunities from veterinary biobanks
  75. Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy‐treated diffuse large B‐cell lymphoma
  76. Big data from small animals: integrating multi-level environmental data into the Dog Aging Project
  77. Social determinants of health and disease in companion dogs: a cohort study from the Dog Aging Project
  78. Identification of a naturally-occurring canine model for early detection and intervention research in high grade urothelial carcinoma
  79. Greater baseline serum C-reactive protein concentrations are associated with reduced survival in dogs receiving cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy for primary nodal diffuse large B-cell lymphoma
  80. Evaluation of Surgical Gown Cuff Contamination During Orthopaedic Surgery in a Veterinary Teaching Hospital
  81. Associations between physical activity and cognitive dysfunction in older companion dogs: results from the Dog Aging Project
  82. Associations between Neighborhood Disadvantage and Dog Walking among Participants in the Dog Aging Project
  83. “Sometimes I just forget them”: Capturing Experiences of Women about Free Menstrual Products in a U.S. Based Public University Campus
  84. Evaluation of cognitive function in the Dog Aging Project: associations with baseline canine characteristics
  85. Antimicrobial susceptibility and risk factors for resistance among Escherichia coli isolated from canine specimens submitted to a diagnostic laboratory in Indiana, 2010–2019
  86. Author Correction: An open science study of ageing in companion dogs
  87. Development and evaluation of a survey instrument to assess veterinary medical record suitability for multi-center research studies
  88. Demographic factors associated with joint supplement use in dogs from the Dog Aging Project
  89. Lifetime prevalence of malignant and benign tumours in companion dogs: Cross‐sectional analysis of Dog Aging Project baseline survey
  90. Biological units of antimicrobial resistance and strategies for their containment in animal production
  91. Evaluation of Cognitive Function in the Dog Aging Project: Associations with Baseline Canine Characteristics
  92. Dog Size and Patterns of Disease History Across the Canine Age Spectrum: Results from the Dog Aging Project
  93. Age and Physical Activity Levels in Companion Dogs: Results From the Dog Aging Project
  94. Once-daily feeding is associated with better health in companion dogs: results from the Dog Aging Project
  95. Associations between physical activity and cognitive dysfunction in older companion dogs: Results from the Dog Aging Project
  96. Social determinants of health and disease in companion dogs: A cohort study from the Dog Aging Project
  97. Dog Models of Aging
  98. Antimicrobial susceptibility and risk factors for resistance amongEscherichia coliisolated from canine specimens submitted to a diagnostic laboratory in Indiana, 2010-2019
  99. An open science study of ageing in companion dogs
  100. Purpose, Partnership, and Possibilities: The Implementation of the Dog Aging Project Biobank
  101. Once-daily feeding is associated with better health in companion dogs: Results from the Dog Aging Project
  102. Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma are Associated with Tumor Immune Signatures and Dog Breed
  103. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF -mutated Urothelial Carcinoma
  104. Quality of reporting of clinical trials in dogs and cats: An update
  105. Veterinary Big Data: When Data Goes to the Dogs
  106. Cryptorchidectomy with a paramedian or inguinal approach in domestic pigs: 47 cases (2000–2018)
  107. IDLY INFECTED: A REVIEW OF INFECTIOUS AGENTS IN POPULATIONS OF TWO- AND THREE-TOED SLOTHS (CHOLOEPUS SPECIES AND BRADYPUS SPECIES)
  108. Variability in tumor margin reporting for soft tissue sarcoma and cutaneous mast cell tumors in dogs: A systematic review
  109. The Golden Retriever Lifetime Study: Assessing factors associated with owner compliance after the first year of enrollment
  110. Public perceptions of threats from mosquitoes in the U.S. using online media analytics
  111. A pilot study of optical neuronavigation‐guided brain biopsy in the horse using anatomic landmarks and fiducial arrays for patient registration
  112. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs
  113. Demographics of dogs and cats with oral tumors presenting to teaching hospitals: 1996–2017
  114. Demographic characteristics, site and phylogenetic distribution of dogs with appendicular osteosarcoma: 744 dogs (2000-2015)
  115. Salivary neoplasia in dogs and cats: 1996–2017
  116. Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma
  117. Association of tibial plateau leveling osteotomy with proximal tibial osteosarcoma in dogs
  118. The intersection of food insecure populations in the Midwest U.S. and rates of chronic health conditions
  119. Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma
  120. Does Flooring Substrate Impact Kennel and Dog Cleanliness in Commercial Breeding Facilities?
  121. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma
  122. Evaluation of three intravenous injectable anaesthesia protocols in healthy adult male alpacas
  123. When is genetic modification socially acceptable? When used to advance human health through avenues other than food
  124. The influence of health concern on travel plans with focus on the Zika virus in 2016
  125. Zoos and public health: A partnership on the One Health frontier
  126. A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas
  127. Laparoscopic Closure of the Nephrosplenic Space in Horses with Nephrosplenic Colonic Entrapment: Factors Associated with Survival and Colic Recurrence
  128. Differences in the geographic distribution of lymphoma subtypes in Golden retrievers in the USA
  129. Abstract 3429: Evidence chronic inflammation is a risk factor for histiocytic sarcoma in Bernese mountain dogs - implications for human histiocytic sarcoma:
  130. Risk Factors Associated with Development of Histiocytic Sarcoma in Bernese Mountain Dogs
  131. A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma
  132. WhatIsInfection Control and Biosecurity
  133. An Investigation of Equine Mesenchymal Stem Cell Characteristics from Different Harvest Sites: More Similar Than Not
  134. Evaluation of plasma muscle enzyme activity as an indicator of lesion characteristics and prognosis in horses undergoing celiotomy for acute gastrointestinal pain
  135. Comparison of two sampling and culture systems for detection ofSalmonella entericain the environment of a large animal hospital
  136. Syndromic surveillance for evaluating the occurrence of healthcare-associated infections in equine hospitals
  137. Using Syndromic Surveillance to Estimate Baseline Rates for Healthcare-Associated Infections in Critical Care Units of Small Animal Referral Hospitals
  138. An Evaluation of Fertility in Arkansas Primocane-fruiting Blackberries
  139. Determining the microbiological criteria for lot rejection from the performance objective or food safety objective